Skip to content
OpenCapital
Get started

Edgewise Therapeutics, Inc. EWTX EBITDA

EBITDA at other companies

PTC Therapeutics logo
PTC TherapeuticsPTCT
$60.37M-93.8%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$83.01M+14.0%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
-$124.73M-2.3%
Scholar Rock logo
Scholar RockSRRK
-$101.68M-32.6%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
——
Cytokinetics logo
CytokineticsCYTK
——

Other financials

Income statement

See full
Operating income-$54.1M-17.7%
Net income-$49.0M-20.1%
EPS (diluted)-$0.46-7.0%

Balance sheet

See full
Cash & equivalents$33.2M-33.5%
Total debt$3.8M-16.8%
Total equity$493.2M+14.8%
Total assets$518.5M+14.1%

Cash flow

See full
Operating cash flow-$42.5M-12.4%
CapEx$260.0K+491%
Free cash flow-$42.8M-12.9%

Valuation

See full
Market cap$3.96B+61.3%
Enterprise value$3.93B+63.5%

Returns & leverage

See full
Return on equity-38.1%+13.4pp
Debt / equity0×0.0×
Current ratio22.6×+1.6×

Where this comes from

Calculated from Edgewise Therapeutics, Inc.’s reported figures.

−$54.1Mebit+
$537.0KDepreciation Depletion & Amortization
=-$53.58M

The official record: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Edgewise Therapeutics, Inc.'s ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Edgewise Therapeutics, Inc.'s EBITDA?
Edgewise Therapeutics, Inc. (EWTX) reported EBITDA of -$53.58M in Q1 2026.
How has Edgewise Therapeutics, Inc.'s EBITDA changed year-over-year?
Edgewise Therapeutics, Inc.'s EBITDA decreased by 17.9% year-over-year, from -$45.45M to -$53.58M.
What is the long-term trend for Edgewise Therapeutics, Inc.'s EBITDA?
Over 4 years (2021 to 2025), Edgewise Therapeutics, Inc.'s EBITDA has grown at a 44.9% compound annual growth rate (CAGR), from -$42.91M to -$189.37M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.